Skip to main
MRNA
MRNA logo

Moderna (MRNA) Stock Forecast & Price Target

Moderna (MRNA) Analyst Ratings

Based on 11 analyst ratings
Hold
Strong Buy 9%
Buy 9%
Hold 55%
Sell 27%
Strong Sell 0%

Bulls say

Moderna is forecasting product sales of $1.73 billion in 2025, with an anticipated increase to $2.15 billion in 2026, signifying strong revenue growth potential. The company's recent $1.5 billion debt deal enhances its balance sheet and provides flexibility for managing uncertainties while capitalizing on future opportunities, illustrating financial prudence. Additionally, improvements in manufacturing efficiency are projected to expand gross margins by 10% over the next three years, underscoring the company’s ability to recover from previous gross margin compressions.

Bears say

The financial analysis reveals a negative outlook for Moderna's stock, primarily due to a significant reduction in COVID vaccine sales, which are projected to decline from $18 billion in 2022 to $6.7 billion in 2023, further impacted by waning vaccination rates. The company faces competitive pressures in the respiratory vaccine space, particularly with established products like Arexvy and Abrysvo, leading to a lowered long-term revenue projection for COVID-related sales from $3.5 billion to $2.5 billion annually. Additionally, Moderna's negotiating position in the European market appears weak, anticipating low sales for both 2024 and 2025, contributing to an overall decrease in its projected enterprise value from $22.12 billion to $21.53 billion.

Moderna (MRNA) has been analyzed by 11 analysts, with a consensus rating of Hold. 9% of analysts recommend a Strong Buy, 9% recommend Buy, 55% suggest Holding, 27% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Moderna and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Moderna (MRNA) Forecast

Analysts have given Moderna (MRNA) a Hold based on their latest research and market trends.

According to 11 analysts, Moderna (MRNA) has a Hold consensus rating as of Dec 13, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32.73, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32.73, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Moderna (MRNA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.